EUVIMEDEUVIMED entdecken
Crossref

Concurrent Chemotherapy With Adjuvant Radiation for Patients With High-risk Locally Advanced Breast Cancer: Safety and Outcomes

Lynn Symonds, Sasha N Swensen, Macklin H Nguyen, Daniel S Hippe, Thomas D Mullen, Stephanie Pang, Angel Liu, Natasha Hunter, Shaveta Vinayak, Kristine E Calhoun, Sara H Javid, Vijayakrishna K Gadi und 4 weitere

Clinical Breast Cancer · 2026-05 · 26 (5) · 63-70

DOI: 10.1016/j.clbc.2026.03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026-05. Verfasst von Lynn Symonds und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington School of Medicine, Seattle, WA; Fred Hutchinson Cancer Center, Clinical Research Division, Seattle,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Chemoradiotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 48 Literaturangaben. Gefördert von: American Society of Clinical Oncology, ASCO Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Concurrent chemoradiation (chemoXRT) enhances the efficacy of adjuvant radiation by radiosensitizing microscopic residual disease and may improve locoregional control. We report our institutional experience using adjuvant chemoXRT for high-risk breast cancer patients. METHODS: We conducted a retrospective study of patients with stage II-III invasive breast cancer treated with chemotherapy, surgery, and adjuvant chemoXRT between 2006 and 2019. The use of chemoXRT was based on provider discretion. Locoregional recurrence (LRR) was the primary outcome. Secondary outcomes included distant recurrence, disease free survival (DFS), overall survival (OS), and toxicity. LRR incidence was estimated with distant recurrence and death as competing risks. DFS and OS were estimated using the Kaplan-Meier method. RESULTS: Forty-two patients met inclusion criteria; 35 (83%) patients received treatment at primary diagnosis and 7 (17%) for a LRR. In the primary setting, 91% had stage III disease. Of the patients who received neoadjuvant chemotherapy (71%), all had residual disease in the breast or lymph nodes. The majority received comprehensive regional nodal irradiation (40, 95%) with a median total dose of 57 Gy (range: 45-68 Gy). Concurrent chemotherapies included capecitabine, cisplatin, or paclitaxel. At median follow-up of 5 years, LRR risk was 7% (95% CI: 2%-21%). DFS was 47% (95% CI: 34%-65%) and OS was 56% (95% CI: 42%-74%). ChemoXRT was well tolerated with expected rates of dermatitis and no new toxicity signals. CONCLUSIONS: Concurrent chemoXRT was safe and showed promise as a method to decrease risk of local recurrence in high-risk patients. Prospective evaluation is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalChemoradiotherapy, AdjuvantAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMiddle AgedAgedAdultNeoplasm StagingChemotherapy, AdjuvantFollow-Up StudiesDisease-Free SurvivalNeoadjuvant Therapy

Stichwörter der Autor:innen

ChemoradiationLocoregional recurrenceStage 2Stage 3Toxicities

Autor:innen und Institutionen

  • Department of Medicine, University of Washington School of Medicine, Seattle, WA; Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA.
  • Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA.
  • Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA.
  • Department of Pharmacy, University of Washington, Seattle, WA.
  • Department of Surgery, University of Washington School of Medicine, Seattle, WA.
  • Department of Medicine, University of Illinois Chicago, Chicago, IL; University of Illinois Cancer Center, Chicago, IL.

Förderung

  • American Society of Clinical Oncology
  • ASCO Foundation

Zitieren

APA

Symonds, L., Swensen, S. N., Nguyen, M. H., Hippe, D. S., Mullen, T. D., Pang, S., Liu, A., Hunter, N., Vinayak, S., Calhoun, K. E., Javid, S. H., Gadi, V. K., Linden, H., Specht, J., Gwin, W., & Kim, J. N. (2026). Concurrent Chemotherapy With Adjuvant Radiation for Patients With High-risk Locally Advanced Breast Cancer: Safety and Outcomes. Clinical Breast Cancer, 26(5), 63-70. https://doi.org/10.1016/j.clbc.2026.03.005

Vancouver

Symonds L, Swensen SN, Nguyen MH, Hippe DS, Mullen TD, Pang S, et al. Concurrent Chemotherapy With Adjuvant Radiation for Patients With High-risk Locally Advanced Breast Cancer: Safety and Outcomes. Clinical Breast Cancer. 2026;26(5):63-70. doi:10.1016/j.clbc.2026.03.005

BibTeX
@article{Symonds2026,
  author = {Symonds, Lynn and Swensen, Sasha N and Nguyen, Macklin H and Hippe, Daniel S and Mullen, Thomas D and Pang, Stephanie and Liu, Angel and Hunter, Natasha and Vinayak, Shaveta and Calhoun, Kristine E and Javid, Sara H and Gadi, Vijayakrishna K and Linden, Hannah and Specht, Jennifer and Gwin, William and Kim, Janice N},
  title = {Concurrent Chemotherapy With Adjuvant Radiation for Patients With High-risk Locally Advanced Breast Cancer: Safety and Outcomes},
  journal = {Clinical Breast Cancer},
  year = {2026},
  volume = {26},
  number = {5},
  pages = {63--70},
  doi = {10.1016/j.clbc.2026.03.005}
}
Kostenlos starten →